Results 221 to 230 of about 870,778 (357)

Neonatal sepsis in South Asia: huge burden and spiralling antimicrobial resistance. [PDF]

, 2019
Agarwal, R, Chaurasia, S, Ellis, S, Sankar, MJ, Sharland, M, Sivanandan, S   +5 more
core   +1 more source

Identification of potential characteristic genes in sepsis utilizing RNA sequencing and gene silence. [PDF]

BMC Immunol
Cao H, Qin N, Zhai Y, Dong C, Huang Z, Huang D, Li J, Yang J, Wang F, Wei W, Wang W.   +10 more
europepmc   +1 more source

Prontosil Album in Puerperal Sepsis

, 1937
M. A. Foulis, J. B. Barr
openalex   +2 more sources

A cooperative release of mitochondrial DNA from platelets and neutrophils drives an interferon signature in systemic sclerosis

Arthritis &Rheumatology, Accepted Article.
Objective Mitochondria are organelles with a hypomethylated circular genome. Mitochondrial DNA (mtDNA) in the systemic circulation has been implicated in inflammation. This study investigates the role of circulating DNA in systemic sclerosis (SSc) and the cellular mechanisms governing its release.
Stavros Giaglis, André N. Tiaden, Simone Häner‐Massimi, Diego Kyburz, Cedric André, Anton Glück, Enrico Ferrero, Stuart Hawtin, Tobias Junt, Ulrich A. Walker   +9 more
wiley   +1 more source

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: the Randomized, Phase 3, TULIP‐SC Study

Arthritis &Rheumatology, Accepted Article.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate‐to‐severe SLE activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly for 52 weeks (1:1 ...
Susan Manzi, Ian N. Bruce, Eric F. Morand, Richard Furie, Yoshiya Tanaka, Kenneth C. Kalunian, Anca Askanase, Patricia Puzio, Emon Khan, Jenny Wissmar, Michael Song, Catharina Lindholm, The TULIP‐SC investigators   +12 more
wiley   +1 more source

Availability, use, efficacy and safety of bevacizumab in European hereditary haemorrhagic telangiectasia centres

British Journal of Clinical Pharmacology, EarlyView.
Introduction Bevacizumab, a vascular endothelial growth factor inhibitor, is used off‐label for treatment of severe anaemia related to epistaxis, gastrointestinal bleeding and/or severe hepatic arteriovenous malformations (HAVM) and right‐sided cardiac failure in patients with hereditary haemorrhagic telangiectasia (HHT).
Pernille D. Haahr, Anette D. Kjeldsen, Annette D. Fialla, Anne‐Emmanuelle Fargeton, Alexandre Guilhem, Elisabetta Buscarini, Freya Droege, Guido Manfredi, Hans‐Jurgen Mager, Jean‐Christophe Saurin, Jens Kjeldsen, Josefien Hessels, Marco C. Post, Robert Mandic, Sanne Boerman, Stefan Kasper‐Virchow, Sören Möller, Urban Geisthoff, Sophie Dupuis‐Girod   +18 more
wiley   +1 more source

Severe <i>Salmonella</i> Infections in AIGAs Immunodeficiency Syndrome: Hyperinflammation and Immune Dysregulation. [PDF]

Infect Drug Resist
Liang S, Chen F, Huang X, Ning Y, Wu S, Hong L, Chen N, Liang H, Wang M, Liang X, He Z.   +10 more
europepmc   +1 more source

Identifying core genes in sepsis by LASSO regression and SVM-RFE algorithm [PDF]

Linlin Luo, Jie Yu
openalex   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

Sepsis-induced coagulopathy: recent insights on the role and clinical application of neutrophil extracellular trap formation. [PDF]

Sci Rep
Zaiema SEGE, Shalaby NA, Mohamed TH, Bayoumy AAM, Galal RESAM.   +4 more
europepmc   +1 more source